Ariad Pharmaceuticals Inc fka ARIA

[vidpok45]

Yes, the important information from.the abstract was the very minimal adverse side effect profile and the fact that the DLT had not been reached. The doctors who will compare 802, 378, and 113 will favor the molecule with the best adverse effects profile if the other variables are comparable. A little nausea and fatigue are minimal problems. The same should hold true for the EGFR population as 113 doesn't compromise native EGFR.